DX-88 (ecallantide)

Phase 2Peptide

Takeda

DX-88 (ecallantide) is one of 24 small molecule programs targeting Angioedema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

AngioedemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Angioedema

#DrugCompanyPhaseTrials

Firazyr

Takeda

Approved

3 2

Adrenaline

SSamson Clinical Operations Pty Ltd

Xolair

2 4

Lanadelumab

Takeda

Phase 3

3 5

Nacl

Bayer

Phase 3

1 6

Nucala

GGlaxo Dba Glaxosmithkline

Phase 2

1 7

DX-2930

Takeda

Phase 3

2 8

Berinert

CSL Behring

Phase 3

1 9

Conestat Alfa

UUniversity Hospital, Basel, Switzerland

Phase 3

1 10

KALBITOR

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angioedema1 trial

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

Completed· Takeda logo

Takeda·Phase 2·NCT01826916·77 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DX-88 (ecallantide). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DX-88 (ecallantide) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DX-88 (ecallantide). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: Takeda

DX-88 (ecallantide)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angioedema1 trial

References

Drug Info

Quick Facts

Related News